share_log

Needham Reiterates Buy on Verrica Pharmaceuticals, Maintains $16 Price Target

Benzinga ·  May 16 11:41

Needham analyst Serge Belanger reiterates Verrica Pharmaceuticals (NASDAQ:VRCA) with a Buy and maintains $16 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment